Spots Global Cancer Trial Database for locally advanced or metastatic solid tumors
Every month we try and update this database with for locally advanced or metastatic solid tumors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors | NCT05957471 | Locally Advance... | Drug: BC3195 fo... | 18 Years - | Biocity Biopharmaceutics Co., Ltd. | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | NCT05581004 | Locally Advance... NSCLC HNSCC Melanoma TNBC Esophageal Canc... Gastric Cancer Cervical Cancer Urothelial Carc... Clear Cell RCC HCC | RO7502175 Atezolizumab | 18 Years - | Genentech, Inc. | |
| Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors | NCT05957471 | Locally Advance... | Drug: BC3195 fo... | 18 Years - | Biocity Biopharmaceutics Co., Ltd. | |
| IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients | NCT05830539 | Locally Advance... | IN10018+PLD IN10018+PLD+Tor... | 18 Years - 75 Years | InxMed (Shanghai) Co., Ltd. | |
| Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors | NCT06293651 | Locally Advance... | DA-4505 DA-4505 + Pembr... | 18 Years - | Dong-A ST Co., Ltd. | |
| Study of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors | NCT05137275 | Locally Advance... | Anti-5T4 CAR-ra... | 18 Years - 80 Years | Shanghai East Hospital | |
| Oral Bioavailability and Mass Balance Trial With Pimasertib | NCT01713036 | Locally Advance... | Pimasertib | 18 Years - 65 Years | Merck KGaA, Darmstadt, Germany | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | NCT05581004 | Locally Advance... NSCLC HNSCC Melanoma TNBC Esophageal Canc... Gastric Cancer Cervical Cancer Urothelial Carc... Clear Cell RCC HCC | RO7502175 Atezolizumab | 18 Years - | Genentech, Inc. | |
| Clinical Study of SM3321 With Solid Tumors | NCT06087770 | Locally Advance... | SM3321 | 18 Years - | Beijing StarMab Biomed Technology Ltd | |
| Clinical Study of SM3321 With Solid Tumors | NCT06087770 | Locally Advance... | SM3321 | 18 Years - | Beijing StarMab Biomed Technology Ltd | |
| Assessment of Safety and Preliminary Clinical Efficacy With BAT6005 in Advanced Malignant Solid Tumors | NCT05116709 | Locally Advance... | BAT6005 injecti... | 18 Years - | Bio-Thera Solutions | |
| MPDL3280A-treatment-IST-UMCG | NCT02478099 | Locally Advance... | MPDL3280A | 18 Years - | University Medical Center Groningen | |
| HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors | NCT05360381 | Locally Advance... Squamous-cell N... | HLX35 | 18 Years - | Shanghai Henlius Biotech | |
| Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors | NCT03736850 | Locally Advance... | CS3006 | 18 Years - | CStone Pharmaceuticals | |
| A Study of TYK-00540 in Adult Patients With Solid Tumors | NCT06246071 | Locally Advance... | TYK-00540 | 18 Years - | TYK Medicines, Inc | |
| IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors | NCT05699811 | Locally Advance... | MSC-IFNα Nab paclitaxel Cyclophosphamid... Anti-PD-1 monoc... | 18 Years - 75 Years | Chinese PLA General Hospital | |
| A Study of YL202 in Selected Patients With Advanced Solid Tumors | NCT06107686 | NSCLC Breast Cancer HNSCC Locally Advance... | YL202 should be... | 18 Years - 75 Years | MediLink Therapeutics (Suzhou) Co., Ltd. | |
| IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients | NCT05830539 | Locally Advance... | IN10018+PLD IN10018+PLD+Tor... | 18 Years - 75 Years | InxMed (Shanghai) Co., Ltd. | |
| A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors | NCT06349811 | Locally Advance... | BL-M05D1 | 18 Years - 75 Years | Sichuan Baili Pharmaceutical Co., Ltd. | |
| Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors | NCT03736850 | Locally Advance... | CS3006 | 18 Years - | CStone Pharmaceuticals | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | NCT05581004 | Locally Advance... NSCLC HNSCC Melanoma TNBC Esophageal Canc... Gastric Cancer Cervical Cancer Urothelial Carc... Clear Cell RCC HCC | RO7502175 Atezolizumab | 18 Years - | Genentech, Inc. | |
| Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors | NCT03478995 | Locally Advance... | GX-I7 | 19 Years - | Genexine, Inc. | |
| Clinical Study of SM3321 With Solid Tumors | NCT06087770 | Locally Advance... | SM3321 | 18 Years - | Beijing StarMab Biomed Technology Ltd | |
| Study of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors | NCT05137275 | Locally Advance... | Anti-5T4 CAR-ra... | 18 Years - 80 Years | Shanghai East Hospital | |
| A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies | NCT05473156 | Locally Advance... Non Small Cell ... Head and Neck S... Esophageal Squa... | AP203 AP203 | 18 Years - | AP Biosciences Inc. | |
| Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors | NCT03565991 | Locally Advance... Genes, BRCA 1 | Avelumab Talazoparib | 18 Years - | Pfizer | |
| A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors | NCT05205109 | Locally Advance... | ATG-037 KEYTRUDA ®( Pem... | 18 Years - | Antengene Corporation | |
| A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). | NCT05012618 | Locally Advance... | LUNA18 Cetuximab | 18 Years - | Chugai Pharmaceutical | |
| First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors | NCT04564417 | Locally Advance... | W0180 Pembrolizumab | 18 Years - | Pierre Fabre Medicament | |
| A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors | NCT06328439 | Locally Advance... | ANS014004 | 18 Years - | Avistone Biotechnology Co., Ltd. | |
| IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors | NCT05699811 | Locally Advance... | MSC-IFNα Nab paclitaxel Cyclophosphamid... Anti-PD-1 monoc... | 18 Years - 75 Years | Chinese PLA General Hospital | |
| A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). | NCT04511845 | Locally Advance... | SPYK04 | 18 Years - | Chugai Pharmaceutical | |
| A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). | NCT04511845 | Locally Advance... | SPYK04 | 18 Years - | Chugai Pharmaceutical | |
| Oral Bioavailability and Mass Balance Trial With Pimasertib | NCT01713036 | Locally Advance... | Pimasertib | 18 Years - 65 Years | Merck KGaA, Darmstadt, Germany | |
| Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer | NCT01449370 | Metastatic Soli... | TAK-117 | 18 Years - | Takeda | |
| MPDL3280A-treatment-IST-UMCG | NCT02478099 | Locally Advance... | MPDL3280A | 18 Years - | University Medical Center Groningen | |
| A Study of TYK-00540 in Adult Patients With Solid Tumors | NCT06246071 | Locally Advance... | TYK-00540 | 18 Years - | TYK Medicines, Inc | |
| IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients | NCT05830539 | Locally Advance... | IN10018+PLD IN10018+PLD+Tor... | 18 Years - 75 Years | InxMed (Shanghai) Co., Ltd. | |
| A Study of YL202 in Selected Patients With Advanced Solid Tumors | NCT06107686 | NSCLC Breast Cancer HNSCC Locally Advance... | YL202 should be... | 18 Years - 75 Years | MediLink Therapeutics (Suzhou) Co., Ltd. | |
| Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors | NCT03478995 | Locally Advance... | GX-I7 | 19 Years - | Genexine, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
